Antibiotic Profile of Pathogenic Bacteria Isolated in Public Hospitals in Northern Jordan

Antibiotic Profile of Pathogenic Bacteria Isolated From Postsurgical Site Infections in Public Hospitals in Northern Jordan

The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Study Overview

• Status: Completed
• Conditions: Bacterial Infections; Surgical Site Infection; Antibiotic Resistant Infection
• Intervention / Treatment: Drug: ciprofloxacin

Detailed Description

Background: Surgical site infections are hospital-acquired, vary from one hospital to another, and can cause significant postoperative morbidity, mortality, and prolonged hospital stay.

Aim: The main aim of the study was to identify the various pathogens associated with surgical site infections and their antibiotic susceptibility in a governmental hospital in northern Jordan.

Methods: Postsurgical wound samples were collected and processed in a microbiology laboratory using standard microbiological techniques. Antibiotic susceptibility tests were performed using 13 antibiotics covering the gram-positive and gram-negative bacteria using the disc diffusion test.

• Study Type: Observational
• Enrollment (Actual): 24

Contacts and Locations

Study Locations

• Jordan
  • Irbid, Jordan, 21163
    • Yarmouk University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

A hospital-based prospective study was carried out in Public-Teaching Hospital in northern Jordan with a total capacity of 400 beds, All patients meet the criteria of getting post-operative wound infections in different surgical wards and ICUs.

Description

Inclusion Criteria:

• Post-Surgical Wound Infection

Exclusion Criteria:

-

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Wound infection; Patients with surgical site infection as diagnosed by the attending physician	Drug: ciprofloxacin; Antibiotics used in vitro n the study; Other Names: ampicillin; tetracycline; clindamycin; trimethoprim-sulfamethoxazole; cefepime; vancomycin; penicillin; erythromycin; norfloxacin; chloramphenicol; gentamicin; amoxicillin/clavulanic acid; oxacillin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Positive culture	Positive swab culture from the wound	August 2019 to October 2019

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gram stain and type of Bacteria	Gram stain and type of Bacteria grown in culture media	August 2019 to October 2019
Antibiotic Susceptibility	Antibiotic Susceptibility to the isolated organisms	August 2019 to October 2019

Collaborators and Investigators

• Sponsor: Yarmouk University
• Investigators: Principal Investigator: Raed M Ennab, Department of Clinical Sciences, Faculty Of Medicine, Yarmouk University

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2019
• Primary Completion (Actual): October 1, 2019
• Study Completion (Actual): October 1, 2019

Study Registration Dates

• First Submitted: October 24, 2021
• First Submitted That Met QC Criteria: October 24, 2021
• First Posted (Actual): November 4, 2021

Study Record Updates

• Last Update Posted (Actual): November 4, 2021
• Last Update Submitted That Met QC Criteria: October 24, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: surgery; antimicrobial; hospital; post-surgical infection
• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Disease Attributes; Bacterial Infections and Mycoses; Wound Infection; Infections; Communicable Diseases; Surgical Wound Infection; Bacterial Infections; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Gastrointestinal Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Protein Synthesis Inhibitors; Antiprotozoal Agents; Antiparasitic Agents; Antimalarials; Folic Acid Antagonists; Cytochrome P-450 CYP1A2 Inhibitors; beta-Lactamase Inhibitors; Anti-Dyskinesia Agents; Anti-Infective Agents, Urinary; Renal Agents; Cytochrome P-450 CYP2C8 Inhibitors; Vancomycin; Erythromycin; Ampicillin; Clindamycin; Gentamicins; Ciprofloxacin; Amoxicillin; Trimethoprim; Sulfamethoxazole; Trimethoprim, Sulfamethoxazole Drug Combination; Clavulanic Acid; Clavulanic Acids; Tetracycline; Penicillins; Cefepime; Norfloxacin; Oxacillin; Chloramphenicol
• Other Study ID Numbers: Antibiotic profile in Jordan

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No